# VEROVACCiNES

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verovaccines

- Industry: Pharmaceuticals
- Headquarters: Halle, Germany
- Website: www.verovaccines.com/
- Total disclosed funding: $1.7M
- Latest round: Series D (Mar 5, 2025)
- Investors on record: 3

## About

VEROVACCiNES GmbH is a specialized company focused on the development of innovative animal vaccines, utilizing advanced technology to enhance veterinary health solutions.VEROVACCiNES GmbH, founded in 2017 in Halle, Germany, develops animal vaccines through a proprietary subunit vaccine platform. The company has completed 2 deals, with its most recent funding round occurring on February 24, 2025, where it raised EUR 1.6 million. The founder's history prior to VEROVACCiNES is not specified.VEROVACCiNES GmbH specializes in the development of animal vaccines through an integrated subunit vaccine platform. The company's core offerings are novel vaccines that utilize recombinant strains of the yeast Kluyveromyces lactis, engineered to stably express antigens that elicit immune responses in target animals. This technology allows for the rapid creation, optimization, and registration of vaccines, providing a streamlined pathway from design to commercialization. VEROVACCiNES addresses health challenges in the veterinary sector by delivering effective vaccines for various animal species, including livestock and pets, primarily marketing its products in Europe and North America to veterinary practices, animal health organizations, and agricultural sectors.VEROVACCiNES GmbH generates revenue through direct sales of its vaccine products to veterinary clinics and animal health distributors, establishing partnerships for broader market reach. The transaction structure is primarily B2B, with veterinary practices ordering vaccines in bulk for their clientele. These sales may involve long-term contracts with agricultural stakeholders requiring consistent access to animal vaccines. The pricing structure is tailored to different buyers' needs, with discounts available for larger orders and multi-year agreements, focusing on delivering high-quality vaccines that meet regulatory standards.In February 2024, VEROVACCiNES GmbH raised EUR 1.6 million in venture funding to support the expansion of its product pipeline. The company is focused on developing new vaccine products to enhance its offerings and aims to penetrate new geographic markets. Specific target regions for expansion have not been disclosed, but the company is committed to utilizing the recent funding to bolster its research and development efforts.

## Funding rounds

- Series D, Mar 5, 2025, $1.7M — High-Tech Gruenderfonds, BAMAC GmbH, Sustainable & Invest
- Seed, Jun 1, 2017 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series D
- BAMAC GmbH — Series D
- Sustainable & Invest — Series D